The Burden of Spinal Muscular Atrophy Type 1 (SMA1) on Caregivers in Japan: First Results of a Global Survey

Author(s)

Toro W1, Tanaka S2, Patel A1, Dabbous O1, Aballéa S3, Motrunich A3, Nomoto M4, Saito K5
1Novartis Gene Therapies, Inc., Bannockburn, IL, USA, 2Novartis Pharma K.K., Tokyo, 13, Japan, 3Creativ-Ceutical, Paris, France, 4Creativ-Ceutical, Tokyo, Japan, 5Institute of Medical Genetics, Tokyo Women’s Medical University, Tokyo, Japan

OBJECTIVES: SMA1, a rare, genetic neuromuscular disease that causes loss of both voluntary motor and bulbar functions, is usually fatal by 2 years of age if untreated. As data on caregiver burden associated with SMA1 are sparse, we sought to describe out-of-pocket expenditures and time costs for the families/caregivers of these patients, as well as healthcare resource use (HCRU). Here, we present initial data reflecting caregiver burden in Japan.

METHODS: An online survey was disseminated by a patient advocacy group (Japan Network for Spinal Muscular Atrophy) and the principal investigator from 10/2020–03/2021. Eligible respondents were voluntary non-healthcare professional adult caregivers.

RESULTS: Forty-eight caregivers (mean age, 38.7 years) managing 50 patients with SMA1 responded. In 40/50 cases (80%), the patient’s mother was the primary caregiver. Mean patient care time was 57.24 hours/week. Of the 50 patients, 35 (70%) had a caregiver who stopped working in order to provide care; eight (16%) had a caregiver who reduced their working hours; three (6%) had a caregiver who changed jobs. Forty-nine (98%) received government subsidies. Impact to income was reported by caregivers representing 36 patients (72%; mean net monthly income reduction, ¥152,223). Mean out-of-pocket costs over the last 6 months were ¥817,670, of which 42% went toward home adaptations, at-home healthcare, and travel for medical appointments. Within the last 6 months, 37 patients (74%) had ≥1 overnight hospitalization (the majority for receiving SMA treatment or for respiratory infection/breathing difficulties).

CONCLUSIONS: Caregivers of patients with SMA1 in Japan reported a substantial burden on their time, employment status, income, and out-of-pocket costs. Lost productivity and HCRU associated with SMA1 impose high direct and indirect societal burdens. Early SMA identification via newborn screening and early access to disease-modifying treatments may reduce these burdens and associated costs. Additional work is ongoing to describe caregiver burden globally.

Conference/Value in Health Info

2021-11, ISPOR Europe 2021, Copenhagen, Denmark

Value in Health, Volume 24, Issue 12, S2 (December 2021)

Code

POSC158

Topic

Economic Evaluation

Topic Subcategory

Work & Home Productivity - Indirect Costs

Disease

Genetic, Regenerative and Curative Therapies

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×